% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Moar:307501,
author = {E. F. Moar and M. Keilholz and G. T. Sheikh and R. A.
Werner and C. Trapp and J. Casuscelli and M. Chaloupka and
W. G. Kunz and P. Kazmierczak and L. Widjaja and S. F. Brose
and C. Eze and F. Walter and C. Belka$^*$ and M. Li and P.
Rogowski and N.-S. Schmidt-Hegemann},
title = {{PSMA} {PET}-{P}ositive {L}ocal {R}ecurrences in the
{P}rostate {B}ed {R}egion and {T}heir {C}overage {B}ased on
{C}linical {T}arget {V}olume {D}elineation {G}uidelines from
{ESTRO}-{ACROP}, {PERYTON}, {FROGG}, {GFRU}, and {RTOG}.},
journal = {Journal of nuclear medicine},
volume = {nn},
issn = {0097-9058},
address = {New York, NY},
publisher = {Soc.},
reportid = {DKFZ-2026-00006},
pages = {nn},
year = {2025},
note = {epub},
abstract = {Accurate clinical target volume (CTV) delineation is
crucial for effective salvage radiotherapy (sRT) following
radical prostatectomy. Current delineation guidelines are
largely based on expert opinion and conventional imaging,
with limited incorporation of prostate-specific membrane
antigen (PSMA) PET/CT data. As PSMA PET/CT enables sensitive
detection of local recurrences (LR), this study aims to
evaluate the benefit of implementing PSMA PET/CT imaging
into CTV delineation guidelines by evaluating spatial
distribution of PSMA PET/CT-positive LR and their coverage
by 5 commonly used guidelines. Methods: We retrospectively
analyzed 77 postprostatectomy patients with 79 LR, staged
with PSMA PET/CT and treated with sRT between 2014 and 2023.
Planning CT scans on which the LR were delineated as gross
tumor volume were further analyzed. The gross tumor volumes
were mapped into a standard patient using a modified
3-dimensional prostate bed template according to the PSMA
PET-guided hypofractionated salvage prostate bed
radiotherapy of biochemical failure after radical
prostatectomy for prostate cancer (PERYTON) guideline.
Coverage of 5 commonly used CTV guidelines, namely, Groupe
Francophone de Radiothérapie Urologique (GFRU), European
Society for Radiotherapy and Oncology-Advisory Committee on
Radiation Oncology Practice (ESTRO-ACROP), PERYTON, Faculty
of Radiation Oncology Genito-Urinary Group (FROGG), and
Radiation Therapy Oncology Group (RTOG) was assessed.
Coverage was categorized as fully $(100\%$ coverage),
partially $(100\%$ < coverage > $0\%),$ or not covered
$(0\%$ coverage). Results: Most LR occurred in the
vesicourethral anastomotic region (52/79, $66\%)$ and
predominantly (73/79, $92\%)$ posteriorly to the midline of
the bladder. Full coverage of LR varied across guidelines:
RTOG (44/79, $56\%),$ PERYTON (41/79, $52\%),$ ESTRO-ACROP
(34/79, $43\%),$ GFRU (31/79, $39\%),$ and FROGG (30/79,
$38\%).$ Partial coverage accounted for the remaining cases,
except for 1 lesion each missed entirely by FROGG, GFRU, and
PERYTON. The posterior, posterolateral, and lateral borders
were the most frequent sites where recurrences exceeded
guideline-defined CTVs. Conclusion: Although current CTV
guidelines achieve acceptable overall coverage, especially
concerning the inferior, anterior, and superior border,
recurrences tend to extend beyond posterior, lateral, and
posterolateral borders, indicating potential areas for
refinement. Incorporation of PSMA PET/CT data into CTV
delineation may improve robustness and reduce the risk of
geographic misses in sRT.},
keywords = {PSMA PET/CT (Other) / clinical target volume delineation
(Other) / local recurrence distribution (Other) / prostate
cancer (Other) / salvage radiotherapy (Other)},
cin = {MU01},
ddc = {610},
cid = {I:(DE-He78)MU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41469156},
doi = {10.2967/jnumed.125.271324},
url = {https://inrepo02.dkfz.de/record/307501},
}